Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-12

AUTHORS

Maaike SM van Mourik, Alexandra Cameron, Marg Ewen, Richard O Laing

ABSTRACT

BACKGROUND: The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology. METHODS: The following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and summarized by World Bank Income Groups. RESULTS: For all measures, there was great variability across surveys. The overall availability of cardiovascular medicines was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment became unaffordable. CONCLUSIONS: The results of this study emphasize the need of focusing attention and financing on making chronic disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal. More... »

PAGES

25

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2261-10-25

DOI

http://dx.doi.org/10.1186/1471-2261-10-25

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032903280

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20534118


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atenolol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Captopril", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost of Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Developing Countries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Services Accessibility", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydrochlorothiazide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Losartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nifedipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "World Health Organization", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "World Health Organization", 
          "id": "https://www.grid.ac/institutes/grid.3575.4", 
          "name": [
            "Student at the Faculty of Medicine, University Medical Centre, Utrecht, The Netherlands", 
            "Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Mourik", 
        "givenName": "Maaike SM", 
        "id": "sg:person.014234700207.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234700207.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Utrecht University", 
          "id": "https://www.grid.ac/institutes/grid.5477.1", 
          "name": [
            "Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland", 
            "Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cameron", 
        "givenName": "Alexandra", 
        "id": "sg:person.0740304265.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740304265.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Action International", 
          "id": "https://www.grid.ac/institutes/grid.500200.7", 
          "name": [
            "Health Action International Global, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ewen", 
        "givenName": "Marg", 
        "id": "sg:person.0733207327.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733207327.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Health Organization", 
          "id": "https://www.grid.ac/institutes/grid.3575.4", 
          "name": [
            "Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laing", 
        "givenName": "Richard O", 
        "id": "sg:person.016637307362.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016637307362.73"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1371/journal.pmed.0030442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002063116"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0895-7061(97)00459-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002360170"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hc4601.099487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016630705"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)60649-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022399028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61762-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032401861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08911-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033133243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.281.17.1580-jfd90003-2-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035873980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)09358-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037226840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1590/s1020-49892007000700006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041255084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1590/s1020-49892004000300005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068108422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2471/blt.06.033647", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070836780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076974706", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077144723", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-12", 
    "datePublishedReg": "2010-12-01", 
    "description": "BACKGROUND: The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology.\nMETHODS: The following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and summarized by World Bank Income Groups.\nRESULTS: For all measures, there was great variability across surveys. The overall availability of cardiovascular medicines was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment became unaffordable.\nCONCLUSIONS: The results of this study emphasize the need of focusing attention and financing on making chronic disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2261-10-25", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024935", 
        "issn": [
          "1471-2261"
        ], 
        "name": "BMC Cardiovascular Disorders", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "name": "Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data", 
    "pagination": "25", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9cbf80ef9361843fe092217f9d0ef22cf2d95396191d39cfd9d0a9e39e599910"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20534118"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100968539"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2261-10-25"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032903280"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2261-10-25", 
      "https://app.dimensions.ai/details/publication/pub.1032903280"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000506.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2261-10-25"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2261-10-25'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2261-10-25'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2261-10-25'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2261-10-25'


 

This table displays all metadata directly associated to this object as RDF triples.

182 TRIPLES      21 PREDICATES      54 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2261-10-25 schema:about N0ed6d32c9e6547e19edf5ac4e7595478
2 N2f90bbe451c24bc88d79e45da3e2ab1c
3 N384931360ba3423f9c228a21ab7dc981
4 N448097c4df624ab6815c653e0ddd34b6
5 N6f91524fce4748459e7543b17e0b6011
6 N78dab94c5d9a4b9382f14a834fddf3a0
7 N828b32366b304b4290a1354d4a1e4e23
8 N986a9adcbf22408fa032b31c811f0017
9 Nbac948edf69e4417ab323ff6fcd36485
10 Nbade8b3dec0a467e99e6de2e9ceaf9d2
11 Nc00285f2b18b4dc7b849dec6bc20d816
12 Nfc5cc778a89a465d8204b47066e761c4
13 anzsrc-for:14
14 anzsrc-for:1402
15 schema:author N9a5d918b898f4307a9b7350e5b58155c
16 schema:citation https://app.dimensions.ai/details/publication/pub.1076974706
17 https://app.dimensions.ai/details/publication/pub.1077144723
18 https://doi.org/10.1001/jama.281.17.1580-jfd90003-2-1
19 https://doi.org/10.1016/s0140-6736(02)08911-0
20 https://doi.org/10.1016/s0140-6736(02)09358-3
21 https://doi.org/10.1016/s0140-6736(08)61762-6
22 https://doi.org/10.1016/s0140-6736(09)60649-8
23 https://doi.org/10.1016/s0895-7061(97)00459-7
24 https://doi.org/10.1161/hc4601.099487
25 https://doi.org/10.1371/journal.pmed.0030442
26 https://doi.org/10.1590/s1020-49892004000300005
27 https://doi.org/10.1590/s1020-49892007000700006
28 https://doi.org/10.2471/blt.06.033647
29 schema:datePublished 2010-12
30 schema:datePublishedReg 2010-12-01
31 schema:description BACKGROUND: The global burden of cardiovascular disease (CVD) continues to rise. Successful treatment of CVD requires adequate pharmaceutical management. The aim was to examine the availability, pricing and affordability of cardiovascular medicines in developing countries using the standardized data collected according to the World Health Organization/Health Action International methodology. METHODS: The following medicines were included: atenolol, captopril, hydrochlorothiazide, losartan and nifedipine. Data from 36 countries were analyzed. Outcome measures were percentage availability, price ratios to international reference prices and number of day's wages needed by the lowest-paid unskilled government worker to purchase one month of chronic treatment. Patient prices were adjusted for inflation and purchasing power, procurement prices only for inflation. Data were analyzed for both generic and originator brand products and the public and private sector and summarized by World Bank Income Groups. RESULTS: For all measures, there was great variability across surveys. The overall availability of cardiovascular medicines was poor (mean 26.3% in public sector, 57.3% private sector). Procurement prices were very competitive in some countries, whereas others consistently paid high prices. Patient prices were generally substantially higher than international references prices; some countries, however, performed well. Chronic treatment with anti-hypertensive medication cost more than one day's wages in many cases. In particular when monotherapy is insufficient, treatment became unaffordable. CONCLUSIONS: The results of this study emphasize the need of focusing attention and financing on making chronic disease medicines accessible, in particular in the public sector. Several policy options are suggested to reach this goal.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf Nd720e93d356f4a1aa095a936fc95ab9e
36 Neabf3dbbd8f648af87a8fd089989ee0d
37 sg:journal.1024935
38 schema:name Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data
39 schema:pagination 25
40 schema:productId N570a211233f549ad835b50aa6c9d84ee
41 N61eb9ea10d024bf3baa786786f4d2856
42 N91654be492a046d78c74c8cd420981de
43 Na146b869d4cc4b12af2d6073ac05d4c9
44 Ncc880f5402fc4c51a9599bb313ba6ed1
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032903280
46 https://doi.org/10.1186/1471-2261-10-25
47 schema:sdDatePublished 2019-04-10T21:35
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N0e9a63a8e28846ca8261ab4fecd8ee61
50 schema:url http://link.springer.com/10.1186%2F1471-2261-10-25
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N0e9a63a8e28846ca8261ab4fecd8ee61 schema:name Springer Nature - SN SciGraph project
55 rdf:type schema:Organization
56 N0ed6d32c9e6547e19edf5ac4e7595478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Atenolol
58 rdf:type schema:DefinedTerm
59 N1accdcefa37b429497766a0e24215711 rdf:first sg:person.016637307362.73
60 rdf:rest rdf:nil
61 N2f90bbe451c24bc88d79e45da3e2ab1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Antihypertensive Agents
63 rdf:type schema:DefinedTerm
64 N384931360ba3423f9c228a21ab7dc981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Captopril
66 rdf:type schema:DefinedTerm
67 N448097c4df624ab6815c653e0ddd34b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Cost of Illness
69 rdf:type schema:DefinedTerm
70 N570a211233f549ad835b50aa6c9d84ee schema:name pubmed_id
71 schema:value 20534118
72 rdf:type schema:PropertyValue
73 N5dcc6ad3d2104df88ff2c72bfd6eb380 rdf:first sg:person.0733207327.04
74 rdf:rest N1accdcefa37b429497766a0e24215711
75 N61eb9ea10d024bf3baa786786f4d2856 schema:name doi
76 schema:value 10.1186/1471-2261-10-25
77 rdf:type schema:PropertyValue
78 N6f91524fce4748459e7543b17e0b6011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Hydrochlorothiazide
80 rdf:type schema:DefinedTerm
81 N78dab94c5d9a4b9382f14a834fddf3a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Health Services Accessibility
83 rdf:type schema:DefinedTerm
84 N7ab023739baa45cba969a9f88c7bb18a rdf:first sg:person.0740304265.25
85 rdf:rest N5dcc6ad3d2104df88ff2c72bfd6eb380
86 N828b32366b304b4290a1354d4a1e4e23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Developing Countries
88 rdf:type schema:DefinedTerm
89 N91654be492a046d78c74c8cd420981de schema:name nlm_unique_id
90 schema:value 100968539
91 rdf:type schema:PropertyValue
92 N986a9adcbf22408fa032b31c811f0017 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Losartan
94 rdf:type schema:DefinedTerm
95 N9a5d918b898f4307a9b7350e5b58155c rdf:first sg:person.014234700207.50
96 rdf:rest N7ab023739baa45cba969a9f88c7bb18a
97 Na146b869d4cc4b12af2d6073ac05d4c9 schema:name dimensions_id
98 schema:value pub.1032903280
99 rdf:type schema:PropertyValue
100 Nbac948edf69e4417ab323ff6fcd36485 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 Nbade8b3dec0a467e99e6de2e9ceaf9d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name World Health Organization
105 rdf:type schema:DefinedTerm
106 Nc00285f2b18b4dc7b849dec6bc20d816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Cardiovascular Diseases
108 rdf:type schema:DefinedTerm
109 Ncc880f5402fc4c51a9599bb313ba6ed1 schema:name readcube_id
110 schema:value 9cbf80ef9361843fe092217f9d0ef22cf2d95396191d39cfd9d0a9e39e599910
111 rdf:type schema:PropertyValue
112 Nd720e93d356f4a1aa095a936fc95ab9e schema:issueNumber 1
113 rdf:type schema:PublicationIssue
114 Neabf3dbbd8f648af87a8fd089989ee0d schema:volumeNumber 10
115 rdf:type schema:PublicationVolume
116 Nfc5cc778a89a465d8204b47066e761c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Nifedipine
118 rdf:type schema:DefinedTerm
119 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
120 schema:name Economics
121 rdf:type schema:DefinedTerm
122 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
123 schema:name Applied Economics
124 rdf:type schema:DefinedTerm
125 sg:journal.1024935 schema:issn 1471-2261
126 schema:name BMC Cardiovascular Disorders
127 rdf:type schema:Periodical
128 sg:person.014234700207.50 schema:affiliation https://www.grid.ac/institutes/grid.3575.4
129 schema:familyName van Mourik
130 schema:givenName Maaike SM
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234700207.50
132 rdf:type schema:Person
133 sg:person.016637307362.73 schema:affiliation https://www.grid.ac/institutes/grid.3575.4
134 schema:familyName Laing
135 schema:givenName Richard O
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016637307362.73
137 rdf:type schema:Person
138 sg:person.0733207327.04 schema:affiliation https://www.grid.ac/institutes/grid.500200.7
139 schema:familyName Ewen
140 schema:givenName Marg
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733207327.04
142 rdf:type schema:Person
143 sg:person.0740304265.25 schema:affiliation https://www.grid.ac/institutes/grid.5477.1
144 schema:familyName Cameron
145 schema:givenName Alexandra
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740304265.25
147 rdf:type schema:Person
148 https://app.dimensions.ai/details/publication/pub.1076974706 schema:CreativeWork
149 https://app.dimensions.ai/details/publication/pub.1077144723 schema:CreativeWork
150 https://doi.org/10.1001/jama.281.17.1580-jfd90003-2-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035873980
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/s0140-6736(02)08911-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033133243
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0140-6736(02)09358-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037226840
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/s0140-6736(08)61762-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032401861
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1016/s0140-6736(09)60649-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022399028
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1016/s0895-7061(97)00459-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002360170
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1161/hc4601.099487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016630705
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1371/journal.pmed.0030442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002063116
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1590/s1020-49892004000300005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068108422
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1590/s1020-49892007000700006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041255084
169 rdf:type schema:CreativeWork
170 https://doi.org/10.2471/blt.06.033647 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070836780
171 rdf:type schema:CreativeWork
172 https://www.grid.ac/institutes/grid.3575.4 schema:alternateName World Health Organization
173 schema:name Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
174 Student at the Faculty of Medicine, University Medical Centre, Utrecht, The Netherlands
175 rdf:type schema:Organization
176 https://www.grid.ac/institutes/grid.500200.7 schema:alternateName Health Action International
177 schema:name Health Action International Global, Amsterdam, The Netherlands
178 rdf:type schema:Organization
179 https://www.grid.ac/institutes/grid.5477.1 schema:alternateName Utrecht University
180 schema:name Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
181 Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
182 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...